Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGON 
CG Oncology, Inc. Common stock (CGON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CGON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $59.73
1 Year Target Price $59.73
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.46% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.73B USD | Price to earnings Ratio - | 1Y Target Price 59.73 |
Price to earnings Ratio - | 1Y Target Price 59.73 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 14.80 - 40.47 | Updated Date 09/17/2025 |
52 Weeks Range 14.80 - 40.47 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -28546.1% |
Management Effectiveness
Return on Assets (TTM) -12.85% | Return on Equity (TTM) -16.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2066555496 | Price to Sales(TTM) 4948.48 |
Enterprise Value 2066555496 | Price to Sales(TTM) 4948.48 | ||
Enterprise Value to Revenue 3750.55 | Enterprise Value to EBITDA - | Shares Outstanding 76247581 | Shares Floating 61016364 |
Shares Outstanding 76247581 | Shares Floating 61016364 | ||
Percent Insiders 1.17 | Percent Institutions 112.6 |
Upturn AI SWOT
CG Oncology, Inc. Common stock
Company Overview
History and Background
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing oncolytic immunotherapies for patients with bladder cancer. Founded in 2010, it has focused on advancing its lead candidate, cretostimogene grenadenorepvec (CG0070), through clinical trials.
Core Business Areas
- Oncolytic Immunotherapy Development: Focuses on the research, development, and clinical testing of cretostimogene grenadenorepvec (CG0070) and other oncolytic immunotherapies targeting bladder cancer and other cancers.
Leadership and Structure
Arthur Kuan serves as the CEO. The company has a typical structure with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Cretostimogene Grenadenorepvec (CG0070): CG0070 is an oncolytic immunotherapy designed to selectively replicate in cancer cells, leading to cell lysis and the release of tumor-associated antigens, which stimulate an immune response. It's being investigated for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guu00e9rin (BCG) therapy. Market share is currently 0%, as the product is not yet approved for commercial sale. Key competitors in the BCG-unresponsive NMIBC space include Merck's Keytruda (approved) and other investigational therapies.
Market Dynamics
Industry Overview
The oncology market, particularly in bladder cancer, is large and growing. There is a significant unmet need for effective therapies for BCG-unresponsive NMIBC, leading to high demand for novel treatments.
Positioning
CG Oncology is positioning itself as a leader in the oncolytic immunotherapy space for bladder cancer, specifically targeting the BCG-unresponsive NMIBC segment. Its competitive advantage lies in the potential efficacy and safety profile of CG0070.
Total Addressable Market (TAM)
The TAM for BCG-unresponsive NMIBC therapies is estimated to be in the billions of dollars annually. CG Oncology is positioned to capture a significant portion of this market if CG0070 is approved. The market continues to grow with the increasing prevalence of bladder cancer and limitations of existing treatments.
Upturn SWOT Analysis
Strengths
- Promising clinical trial data for CG0070
- Experienced management team
- Focus on a specific unmet medical need
- Proprietary technology platform
Weaknesses
- Reliance on a single lead candidate
- Limited commercial infrastructure
- High cash burn rate typical of development-stage biopharma
- Dependence on successful completion of clinical trials and regulatory approval
Opportunities
- Expansion of CG0070 into other cancer indications
- Partnerships with larger pharmaceutical companies
- Potential for accelerated regulatory approval
- Increasing awareness of oncolytic immunotherapy
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other therapies
- Economic downturn impacting funding for biotech companies
Competitors and Market Share
Key Competitors
- MRK
- BLFS
- VYGR
Competitive Landscape
CG Oncology is competing in a landscape dominated by established players like Merck (Keytruda). Success hinges on demonstrating superior efficacy and safety compared to existing therapies and other investigational agents. BLFS and VYGR are earlier stage companies exploring alternative approaches for NMIBC.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the progression of CG0070 through clinical trials.
Future Projections: Future growth is dependent on successful commercialization of CG0070 and potential expansion into other indications. Analyst estimates are subject to clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing the BONDER-002 trial and preparing for potential commercial launch.
Summary
CG Oncology is a development-stage company with a promising lead candidate in CG0070. The company's success depends on the results of its clinical trials and subsequent regulatory approval. While the company has a focused approach and a strong management team, it faces risks associated with clinical development, competition, and funding. The large unmet need in BCG-unresponsive NMIBC presents a significant market opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CG Oncology, Inc. Common stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2024-01-25 | Chairman & CEO Mr. Arthur Kuan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://cgoncology.com |
Full time employees 113 | Website https://cgoncology.com | ||
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.